Drug Topics August 5, 2024
An interim FTC report outlined how the rise of vertical integration and concentration has led to devastating results for both patients and fragile pieces of the health care delivery system.
Created with the mission of reining in costs, pharmacy benefit managers (PBMs) appear to have had the opposite effect for the American consumer—driving up drug costs, pushing independent pharmacies into oblivion, and creating incentives that crush low-cost options such as generics and biosimilars, according to a scathing report issued by the Federal Trade Commission (FTC).1
If Congress takes action against PBMs later this year, July 2024 will mark the month when things got serious. This follows a multiyear effort to highlight how PBMs are undermining pharmacists, physicians, and patients alike....
Today's Sponsors
Today's Sponsor